Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 40

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 40
---
 products, duplicate our products, or design around our patents.                                                    |

The patent prosecution process
is expensive and time-consuming, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent
applications at a reasonable cost or in a timely manner, or in all jurisdictions. We may choose not to seek patent protection for certain
innovations and may choose not to pursue patent protection in certain jurisdictions, and under the laws of certain jurisdictions, patents
or other intellectual property rights may be unavailable or limited in scope. It is also possible that we will fail to identify patentable
aspects of our developments before it is too late to obtain patent protection.

In addition, the laws of
foreign jurisdictions may not protect our rights to the same extent as the laws of the United States. For example, most countries outside
of the United States do not allow patents for methods of treating the human body. This may preclude us from obtaining method patents
outside of the United States having similar scope to those we have obtained or may obtain in the future in the United States. Changes
in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our
patents or narrow the scope of our patent protection.

Moreover, we may be subject
to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, or patent offices in foreign
jurisdictions, or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference
proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding
or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology and compete
directly with us, without payment to us.

The issuance of a patent
is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent
offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims
being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing
similar or identical products and techniques, or limit the duration of the patent protection of our technology.

<div align='center'>30</div>

While we